Constellation Pharmaceuticals (NASDAQ:CNST) Upgraded to Buy at ValuEngine

Constellation Pharmaceuticals (NASDAQ:CNST) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, ValuEngine reports.

CNST has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Constellation Pharmaceuticals in a report on Wednesday, June 5th. Zacks Investment Research lowered shares of Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, July 15th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $17.29.

NASDAQ CNST traded down $0.18 during trading hours on Thursday, reaching $9.07. The company’s stock had a trading volume of 18,234 shares, compared to its average volume of 73,670. The company has a market cap of $234.07 million and a PE ratio of -1.81. The company has a debt-to-equity ratio of 0.25, a quick ratio of 6.92 and a current ratio of 6.92. The business’s 50-day moving average price is $9.91. Constellation Pharmaceuticals has a fifty-two week low of $4.01 and a fifty-two week high of $14.04.

Constellation Pharmaceuticals (NASDAQ:CNST) last released its earnings results on Wednesday, May 8th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.80) by $0.05. As a group, equities research analysts forecast that Constellation Pharmaceuticals will post -3.12 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in CNST. BNP Paribas Arbitrage SA lifted its holdings in Constellation Pharmaceuticals by 4,092.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 3,312 shares of the company’s stock valued at $45,000 after purchasing an additional 3,233 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Constellation Pharmaceuticals by 16.9% during the 4th quarter. Geode Capital Management LLC now owns 13,735 shares of the company’s stock worth $55,000 after acquiring an additional 1,987 shares during the period. Wade G W & Inc. purchased a new position in shares of Constellation Pharmaceuticals during the 1st quarter worth about $166,000. Northern Trust Corp lifted its holdings in shares of Constellation Pharmaceuticals by 12.4% during the 4th quarter. Northern Trust Corp now owns 51,008 shares of the company’s stock worth $204,000 after acquiring an additional 5,624 shares during the period. Finally, Rhumbline Advisers purchased a new position in shares of Constellation Pharmaceuticals during the 1st quarter worth about $221,000. Institutional investors own 64.38% of the company’s stock.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.

Featured Story: How to Track your Portfolio in Google Finance

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Constellation Pharmaceuticals (NASDAQ:CNST)

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.